Compare Koninklijke Philips NV (PHG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Sana Biotechnology Inc — how do they compare? Koninklijke Philips NV trades at $24.94 (market cap $24.84B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Koninklijke Philips NV is far larger — about 24.1× Sana Biotechnology Inc's market cap, and Koninklijke Philips NV pays a 4.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PHG | SANA | |
|---|---|---|
Market Cap | $24.84B | $1.03B |
Sector | Health | Health |
52-Week High | $32.91 | $5.92 |
52-Week Low | $25.02 | $2.68 |
Enterprise Value | $31.44B | $946.04M |
Dividend Yield | 4.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $0.57 beating expectations of $0.40, and positive net income of $895M in 2025 reversing previous losses. Recent product launches in women's health and AI-powered medical devices demonstrate innovation momentum.
The outlook is mixed with strong fundamentals and analyst support (36% buy ratings) offset by technical weakness. Key opportunities include margin expansion and new product adoption, while risks involve cybersecurity threats and competitive pressures in healthcare technology.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
